arrow
A

Alex H. Chang

School of Life Sciences
H指数:31
被引数:3,342

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy

基线18F-FDG PET/CT对BCMA CAR T细胞治疗后复发或难治性多发性骨髓瘤患者毒性和预后的预测价值

2025-12-130
PRE
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial

CD19靶向和BCMA靶向CAR-T细胞的联合输注治疗难治性系统性红斑狼疮:一项1期临床试验

2025-09-240
PRE
BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial

BCMA/GPRC5D双特异性CAR T细胞疗法治疗伴有髓外病变的复发/难治性多发性骨髓瘤:一项单中心、单臂、I期临床试验

2025-05-190
OA
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial

达沙替尼和CAR T细胞疗法在初诊费城染色体阳性急性淋巴细胞白血病中的应用:一项非随机临床试验

2025-04-170
PRE
Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer

转移性去势抵抗性前列腺癌的不良预后基因表达模式

2025-02-220
OAAI
Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission

病例报告: 供体来源的CLL-1嵌合抗原受体T细胞治疗复发/难治性急性髓系白血病缓解后过渡到异基因造血干细胞移植

2024-05-133
OAAI